You are here

India's cough syrup ban hits Pfizer, Abbott units

Their products are among 344 fixed-dose combination drugs prohibited by regulators

BT_20160315_NAHPFIZER15_2165829.jpg
Shares of Pfizer Ltd fell as much as 8 per cent after the drugmaker said it stopped selling its version of the medicine that has just been banned by Indian regulators.

Mumbai

PFIZER Inc and Abbott Laboratories on Monday said they would comply with a ban on a popular cough syrup in India after it was added to a local list of prohibited drugs, sending shares in the US firms' Indian subsidiaries tumbling.

Pfizer's Corex-brand syrup and Abbott's

sentifi.com

Market voices on: